---
title: "Publications"
author: "Henrik Vitus Bering Laursen"
format:
    html:
        toc: true
---

## Mainly Epidemiology

### [Critique of Health economic model assumptions using real-world data](https://doi.org/10.1101/2025.06.20.25329913)

|Title|Summary|
|:---|:---|
|*Health economic model assumptions of pharmaceutical treatment paths compared with real-world evidence for patients with type 2 diabetes: A nationwide cohort study*|Using registry cohort from a [previous study](https://doi.org/10.1101/2025.06.20.25328883), we examined treatment regimen and time to insulin, by starting drug, and compared the findings with assumptions used in health economic models.|

::: {.callout-note collapse="true"}
## Highlight from article

![Figure 2: The plot for the Aalen-Johansen cumulative incidence function with 95% confidence intervals. Stratified by inclusion period. Truncated at 3 years for better comparability.](https://www.medrxiv.org/content/medrxiv/early/2025/06/21/2025.06.20.25329913/F2.large.jpg?width=800&height=600&carousel=1)

:::

---

### [Nationwide cohort of Danish people with type 2 diabetes - what are the treatment patterns?](https://doi.org/10.1101/2025.06.20.25328883)

|Title|Summary|
|:---|:---|
|*Trends in anti-hyperglycaemic drug usage among Danish type 2 diabetes patients on second-line treatment and beyond: A nationwide cohort study*|Creating a nationwide registry cohort of Danish people with T2D on newer antidiabetic drugs (SGLT2, GLP1, DPP4), and following drug utilization and treatment patterns.|

::: {.callout-note collapse="true"}
## Highlight from article

![Figure 3: Depicted here are the proportions of each drug class at each treatment stage for the cohort, i.e. the first to the sixth introduced drug for each individual patient, over time. Omitted bars in 2012 are due to insufficient or lacking data. MET = metformin, SU = sulfonylurea, DPP4 = dipeptidyl peptidase-4 inhibitors, GLP1 = glucagon-like peptide-1 receptor agonists, SGLT2 = sodium glucose co-transporter-2 inhibitor, TZD = thiazolidinedions, AGI = alpha-glucosidase inhibitor, INS = insulin, METandDPP4 = metformin and DPP4 combination, OTHERS = all other anti-hyperglycaemic drugs.](https://www.medrxiv.org/content/medrxiv/early/2025/06/21/2025.06.20.25328883/F3.large.jpg?width=800&height=600&carousel=1)

:::

## Systematic reviews

### [Rigorously checking the quality of real-world quality improvement](https://doi.org/10.1186/s12913-019-4482-6)

|Title|Summary|
|:---|:---|
|*Can quality improvement improve the quality of care? A systematic review of reported effects and methodological rigor in plan-do-study-act projects*|Systematic review of 120 Quality Improvement studies. A comparison of ideal versus real-world Plan-Do-Study-Act usage in quality improvement practice.|

::: {.callout-note collapse="true"}
## Highlight from article
![a) Bar-chart depicting how often the four key features were used across the projects. b) Bar-chart depicting the number of projects, which had used zero to four key features](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12913-019-4482-6/MediaObjects/12913_2019_4482_Fig3_HTML.png)
:::

### [Going through cost-effectiveness models comparing GLP1 and SGLT2 for treatment of type 2 diabetes](https://doi.org/10.1007/s40273-023-01268-5)

|Title|Summary|
|:---|:---|
|*A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus*|Systematic review of 50 cost-effectiveness analyses using decision-analytical modelling. Methodological critique of state of the art decision-analytical models, uncovering novel insights.|

::: {.callout-note collapse="true"}
## Highlight from article

![Fig. 1 Flow-chart for study selection, adapted from the PRISMA-guidelines for the reporting systematic reviews [32]. DAM decision-analytical model, nNIAD Non-insulin antidiabetic drugs](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0896/10570198/ba90125f9515/40273_2023_1268_Fig1_HTML.jpg)

:::

### [Risk of diabetic ketoacidosis after GLP1 or SGLT2](https://doi.org/10.2174/1574886315666200819114629)

|Title|Summary|
|:---|:---|
|*Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use*|Conducted everything from data extraction to making a publication ready manuscript, risk of diabetic ketoacidosis. The study highlights connection between SGLT2s and diabetic ketoacidosis.|

::: {.callout-note collapse="true"}
## Highlight from article

![](https://www.eurekaselect.com/images/graphical-abstract/cds/16/1/big-003.jpg)

:::

### [Diabetes and amputations](https://doi.org/10.1111/dme.14251)

|Title|Summary|
|:---|:---|
|*Twenty years with diabetes and amputations: a retrospective population-based cohort study*|Setting up a case-control study using registry data. Learned a lot of basic data cleaning, wrangling, and statistical programming making for this paper|

### [Danish hip fracture trends over 20 years](https://doi.org/10.1016/j.bone.2019.115083)

|Title|Summary|
|:---|:---|
|*Age at hip fracture and life expectancy in Denmark â€“ Secular trends over two decades*|In less than a week I created a dataset for the purpose of examining hip fractures and quality checked it for publication-ready analyses|


